Emergence of clinical Escherichia coli isolates with decreased susceptibility to ceftazidime and synergic effect with co-amoxiclav due to SHV-1 hyperproduction

Journal of Antimicrobial Chemotherapy

Volumn 42, Issue 4, 1998, Pages 535-538

  Miró, Elisenda ^a   Del Cuerpo, Margarita ^a   Navarro, Ferran ^a   Sabaté, Montserrat ^a   Mirelis, Beatriz ^a   Prats, Guillermo ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; BETA LACTAMASE; CEFAZOLIN; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFUROXIME; PIPERACILLIN; TICARCILLIN;

AGAR GEL DIFFUSION; ANTIBIOTIC SENSITIVITY; ARTICLE; ENZYME ANALYSIS; ENZYME SYNTHESIS; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; BETA-LACTAMASES; CEFTAZIDIME; DNA, BACTERIAL; DRUG THERAPY, COMBINATION; ELECTROPHORESIS, GEL, PULSED-FIELD; ESCHERICHIA COLI; HUMANS; ISOELECTRIC FOCUSING; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; SEROTYPING; SPAIN;

EID: 0031685290     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/42.4.535     Document Type: Article

References (10)

1. Livermore, D. M. (1995). β-Lactamases in laboratory and clinical resistance. Clinical Microbiology Review 8, 557-84.
2. Petit, A., Ben Yaghlane-Bouslama, H., Sofer, L. & Labia, R. (1992). Does high level production of SHV-type penicillinase confer resistance to ceftazidime in Enterobacteriaceae? FEMS Microbiology Letters 92, 89-94.
3. Du Bois, S. K., Marriott, M. S. & Amyes, S. G. (1995). TEM- and SHV-derived extended-spectrum β-lactamases: relationship between selection, structure and function. Journal of Antimicrobial Chemotherapy 35, 7-22.
4. Rasheed, J. K., Jay C., Metchock, B., Berkowitz, F., Weigel, L., Crellin, J. et al. (1997). Evolution of extended-spectrum β-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrobial Agents and Chemotherapy 41, 647-53.
5. Sanders, C. C., Iaconis, J. P., Bodey, G. P. & Samonis, G. (1988). Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 β-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disc-diffusion tests. Antimicrobial Agents and Chemotherapy 32, 1365-9.
6. National Committee for Clinical Laboratory Standards. (1995). Performance Standards for Antimicrobial Susceptibility Testing; Sixth Informational Supplement: Approved Standard M100-S6. NCCLS, Villanova, PA.
7. Barthélemy, M., Guionie, M. & Labia, R. (1978). β-Lactamases: determination of their isoelectric points. Antimicrobial Agents and Chemotherapy 13, 695-8.
8. Nüesch-Inderbinen, M. T., Hächler, H. & Kayser, F. H. (1996). Detection of genes coding for extended-spectrum SHV β-lactamases in clinical isolates by a molecular genetic method, and comparison with the Etest. European Journal of Clinical Microbiology and Infectious Diseases 15, 398-402.
9. Richard, C. (1981). Une méthode simple de marquage épidémiologique: la biotypie, application à Enterobacter cloacae et Escherichia coli. Bulletin de l'Association des Anciens Élèves de l'Institut Pasteur 87, 14-21.
10. Nüesch-Inderbinen, M. T., Hächler, H. & Kayser, F. H. (1995). New system based on site-directed mutagenesis for highly accurate comparison of resistance levels conferred by SHV β-lactamases. Antimicrobial Agents and Chemotherapy 39, 1726-30.